8-K: Silence Therapeutics Acquired by Merck, Q3 Results Show Reduced Losses

Silence Therapeutics announced its Q3 2026 financial results, highlighting positive Phase 2 trial data for divesiran and its definitive agreement to be acquired by Merck KGaA, Darmstadt, Germany.

Summary

• Silence Therapeutics reported its third quarter 2026 financial results and provided business updates.
• The company announced positive topline results from its Phase 2 SANRECO trial of divesiran for polycythemia vera, suggesting a potentially best-in-class profile with quarterly dosing.
• These SANRECO Phase 2 results will be presented at the American Society of Hematology (ASH) 2026 Annual Meeting.
• A significant development is the definitive agreement for Silence Therapeutics to be acquired by Merck KGaA, Darmstadt, Germany, with the transaction expected to close in Q1 2027.
• As of September 30, 2026, the company had $247.7 million in cash and cash equivalents, including $201.3 million from an August 2026 public offering.
• Research and development (R&D) expenses decreased to $9.3 million in Q3 2026 from $20.5 million in Q3 2025, primarily due to the completion of Phase 3 readiness for zerlasiran and reduced personnel costs.
• General and administrative (G&A) expenses also decreased to $4.9 million from $5.8 million, attributed to cost reduction efforts.
• The net loss for Q3 2026 was $12.4 million ($0.08 per share), an improvement from a net loss of $21.0 million ($0.15 per share) in Q3 2025.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, primarily driven by the acquisition news and positive clinical trial results, despite ongoing net losses.

Positives

• Positive topline results from the Phase 2 SANRECO trial of divesiran for polycythemia vera, indicating potential for a best-in-class profile with quarterly dosing.
• The acquisition by Merck KGaA, Darmstadt, Germany, provides a significant valuation event for shareholders.
• Reduced net loss in Q3 2026 to $12.4 million from $21.0 million in Q3 2025.
• Significant decrease in R&D expenses to $9.3 million from $20.5 million year-over-year.
• Substantial cash position of $247.7 million as of September 30, 2026, bolstered by a recent public offering.
• G&A expenses were reduced by $0.9 million year-over-year.

Negatives

• The company continues to report net losses, with a loss of $12.4 million in Q3 2026.
• Despite reductions, R&D expenses remain substantial at $9.3 million for the quarter.
• The acquisition is subject to customary closing conditions and regulatory approvals, introducing uncertainty.
• The company has a history of significant operating losses, with an accumulated deficit of $601.9 million as of September 30, 2026.

Risks

• The proposed acquisition by Merck KGaA, Darmstadt, Germany, is subject to customary closing conditions, including regulatory and shareholder approvals, and the sanction of the High Court of Justice of England and Wales, which could delay or prevent its completion.
• There is a risk of shareholder or other litigation in connection with the proposed transaction, potentially causing expense or delay.
• Pharmaceutical product development is inherently uncertain, with risks related to clinical success and the regulatory approval process.
• Disruption from the proposed acquisition could make it more difficult to conduct business as usual or maintain relationships with customers, employees, or suppliers.
• The market price of the company's American Depositary Shares or ordinary shares could be affected by the announcement of the acquisition or any further announcements or consummation.
• Other risks include regulatory initiatives, changes in tax laws, market volatility, and uncertainties affecting the company as described in its SEC filings.

Future Outlook

The company's future is largely tied to the successful completion of its acquisition by Merck KGaA, Darmstadt, Germany, expected in the first quarter of 2027. Positive clinical data for divesiran supports its potential therapeutic value, which will be further evaluated under Merck's stewardship.

Management Comments

• The positive topline results from our Phase 2 SANRECO trial of divesiran are a significant milestone, reinforcing the potential of our siRNA technology to address diseases with high unmet need.
• The proposed acquisition by Merck KGaA, Darmstadt, Germany, represents a compelling opportunity to accelerate the development and potential commercialization of our innovative therapies.
• We are pleased with the progress made in reducing our operating expenses while continuing to advance our pipeline.

Industry Context

StockSavvy.ai notes that the acquisition of Silence Therapeutics by Merck KGaA, Darmstadt, Germany, aligns with a broader trend of large pharmaceutical companies acquiring innovative biotechnology firms, particularly those with promising pipeline assets in areas like RNA interference (RNAi) therapeutics, to bolster their R&D capabilities and product portfolios.

Comparison to Industry Standards

• The net loss of $12.4 million for Q3 2026, while significant, represents an improvement over the $21.0 million loss in the prior year's quarter, indicating progress in cost management relative to prior performance.
• R&D expenses of $9.3 million for Q3 2026 are lower than the $20.5 million in Q3 2025, reflecting a common industry practice of optimizing R&D spend as programs mature or strategic shifts occur.
• The cash position of $247.7 million is robust for a clinical-stage company, providing ample runway, especially in light of the pending acquisition.

Legal Proceedings

• Potential shareholder or other litigation in connection with the proposed acquisition transaction.

Stakeholder Impact

• Shareholders: The acquisition by Merck KGaA, Darmstadt, Germany, offers a potential liquidity event and realization of value for shareholders.
• Employees: The acquisition may lead to changes in employment, integration into Merck's operations, or potential redundancies.
• Suppliers and Customers: Business relationships may be impacted by the change in ownership and integration into Merck's broader operations.

Next Steps

• The primary next step is the completion of the acquisition by Merck KGaA, Darmstadt, Germany, expected in Q1 2027.
• Presentation of Phase 2 SANRECO trial results for divesiran at the ASH 2026 Annual Meeting (December 12-15, 2026).
• Filing of a proxy statement with the SEC in connection with the proposed acquisition.

Key Dates

Recommendation

The pending acquisition by Merck KGaA, Darmstadt, Germany, creates a binary outcome. While the acquisition offers a positive exit, the ongoing net losses and the inherent risks in drug development warrant a hold position until the transaction is finalized and the terms are fully understood in the context of Merck's strategic integration.

Keywords

siRNA therapies, clinical-stage, polycythemia vera, drivesiran, Merck acquisition, biotechnology, drug development, financial results